Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone650-521-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$78.63 million
Profitability
Miscellaneous
Employees401
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Monday, February, 11th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.08. The biotechnology company had revenue of $19.53 million for the quarter, compared to analysts' expectations of $21.08 million. Pacific Biosciences of California had a negative net margin of 130.44% and a negative return on equity of 94.50%. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
What price target have analysts set for PACB?
4 analysts have issued 1 year target prices for Pacific Biosciences of California's stock. Their forecasts range from $3.80 to $8.00. On average, they expect Pacific Biosciences of California's stock price to reach $6.5750 in the next year. This suggests that the stock has a possible downside of 10.4%. View Analyst Price Targets for Pacific Biosciences of California.
What is the consensus analysts' recommendation for Pacific Biosciences of California?
What are Wall Street analysts saying about Pacific Biosciences of California stock?
Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
- 1. According to Zacks Investment Research, "Pacific Biosciences has been gaining grounds in the MedTech space, thanks to strong Sequel performance, which witnessed record bookings. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced that it is acquiring the former for $8 per Pacific Biosciences share (in an all-cash transaction). Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019. Reflective of these, the company outperformed its industry in a year’s time. On the flip side, dull performance in the service and other revenue segment stemming from lower instrument revenues is a headwind. The DNA sequencing market is rife with competition. Sales in Europe declined considerably in the last-reported quarter. Also, higher operating expenses are likely to mar prospects." (4/16/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are downgrading the shares of PACB to PACB’s announced acquisition by ILMN (Not Covered). On Nov. 1, after the market close, PACB announced an agreement to be acquired by ILMN for $8 per share, or ~$1.2B total EV. We view the likelihood of a higher bidder to be low. We also think regulatory risk to the deal remains low. The acquisition is expected to be completed mid-2019. We spoke to a number of industry participants to assess the likelihood of a higher bidder and regulatory approval." (11/12/2018)
Has Pacific Biosciences of California been receiving favorable news coverage?
News articles about PACB stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Precipio (PRPO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), PositiveID (PSID) and Arrayit (ARYC).
What other stocks do shareholders of Pacific Biosciences of California own?
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
- Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
- Dr. Stephen Turner, Co-Founder & CTO (Age 51)
- Dr. Jonas Korlach Ph.D., Chief Scientific Officer
Who are Pacific Biosciences of California's major shareholders?
Pacific Biosciences of California's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Havens Advisors LLC (0.42%) and Syquant Capital Sas (0.33%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.
Which institutional investors are buying Pacific Biosciences of California stock?
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $7.34.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $1.11 billion and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.
What is Pacific Biosciences of California's official website?
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
